Therapeutic Drug Monitoring of Long-Acting Rilpivirine and Cabotegravir for Treatment of HIV-1 Infection-A Case Series of Five Patients With One Virologic Failure After Development of Two-Class Resistance

Affiliations

• ¹ Institute for Tropical Medicine, Eberhard-Karls University Tübingen, Tübingen, Germany.
• ² Division of Infectious Diseases, Department of Internal Medicine II, University of Würzburg Medical Center, Würzburg, Germany.
• ³ Institute of Medical Microbiology, Jena University Hospital/Friedrich-Schiller-University, Jena, Germany.
• ⁴ Division of Infectious Diseases and Tropical Medicine, Leipzig University Medical Center, Leipzig, Germany.
• ⁵ Medizinische Klinik und Poliklinik IV, LMU University Hospital, Ludwig-Maximilians-Universität Munich, Germany.
• ⁶ Jena University Hospital/Friedrich-Schiller-University, Jena, Germany.
• ⁷ Institute of Immunology and Genetics, Medical Laboratory, Kaiserslautern, Germany.
• ⁸ Institute of Clinical and Molecular Virology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
• ⁹ Medical Department II, Section Infectious Diseases, University Medical Center, Frankfurt am Main, Germany.
• ¹⁰ Institute of Infectious Diseases and Infection Control, Jena University Hospital/Friedrich-Schiller-University, Jena, Germany.